2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2196

Treprostinil Use in Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): Review of Worldwide Experience to Date
Abstract Number: 506

Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis
Abstract Number: 816

TRNT1 Missense Mutations Define a New Periodic Fever Syndrome
Abstract Number: 738

Troponin T as a Diagnostic and Prognostic Biomarker of Primary Cardiac Involvement in Systemic Sclerosis
Abstract Number: 2042

Tuberculin Conversion in Patients with Autoimmune Arthropathies Receiving Biologic Therapy
Abstract Number: 2157

Tuberculosis Reactivation Risk in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors: A Turkish Experience with Higher Mortality and Different Background Diseases
Abstract Number: 2959

Twenty-Eight Loci That Influence Serum Urate Levels: Analysis of Association with Gout
Abstract Number: 2095

Two Novel Serum Urate Levels Associated Genetic Loci Identified By GWAS in European Were Confirmed in Chinese Han Population
Abstract Number: 540

Two Years Sacroiliac Radiographic Progression Rate and Influence of Baseline Markers of Inflammation in Recent Onset Spondyloarthritis
Abstract Number: 1047

Type I and II Interferon Signatures in Sjogren’s Syndrome: Contributions in Distinct Clinical Phenotypes and Sjogren’s Related Lymphomagenesis
Abstract Number: 654

Type I Interferon Induces the Depletion and Dysfunction of Endothelial Progenitor Cells in Gld. ApoE-/- C57BL/6 Mice
Abstract Number: 1202

Type I Interferon Promotes Inflammatory Cytokine Production By Inhibiting Mir-146a Maturation in SLE
Abstract Number: 1076

U.S. Geographic Trends in the Distribution and Treatment Practices of Juvenile Systemic Lupus Erythematosus: An Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 869

UBE2L3 genotype Influences Plasma Cell Proliferation in Systemic Lupus Erythematosus By Regulation of NF-κB By the Linear Ubiquitination Assembly Complex
Abstract Number: 2678

UC-MSCs Inhibit T Cell Autophagy and Apoptosis in Patients with Systemic Lupus Erythematosus through Mitochondrial Transfer

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].